Buradasınız

Anasayfa » Content

KRONİK HEMODİYALİZ HASTALARINDA LIPID PEROKSIDASYONU

LIPID PEROXIDATION IN CHRONIC HEMODIALYSIS PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
In this study, we aimed to investigate the condition of oxidative stress and antioxidative defence system in chronic hemodialysis patients. So, the malondialdehyde (MAD) levels, as the marker of lipid peroxidation, and the activities of glutathione peroxidase (GPx), catalase and superoxide dismutase (SOD) being components of enzymatic anticxidative defence system were measured in 20 patients, mean age 49,4±14.Iyears with chronic hemodialysis and 16 healthy volunteers, mean age 45,0±l 1.4 years. Both erythrocyte and plasma MDA levels of the hemodialysis patients were found to be increased compared to the control group (p<0.0001). GPx and SOD enzyme activity were lower in hemodialysis patients group compared to the control group (p<0.000 land p<0.0001, respectively) and catalase enzyme activity was higher in the group of hemodialysis patients compared to the control group (p<0.0001). In hemodialysis patients groups, both erythrocyte and plasma MDA level was lower after the dialysis compared to the level before hemodialysis and GPx and enzyme activity were found to be high after hemodialysis compared to the level before hemodialysis, (p<0.0001, p<0.05 and p<0.05, respectively). We could find no difference in SOD enzyme activity before and after hemodialysis (p>0.05). It was concluded as a result of this study that LP was high in hemodialysis patients compared to healthy subjects ant that hemodialysis treatment reduced oxidative stress.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada kronik hemodiyaliz hastalarında diyaliz öncesi ve diyaliz sonrası serbest radikal ve antioksidanların durumunu araştırmayı amaçladık. Bunun için yaş ortalaması 49,4±14.1 yıl olan 20 hemodiyaliz hastası ile yaş ortalaması 45.0±11.4 yıl olan 16 sağlıklı kontrol grubunda lipid peroksidayonu (LP) 'nun bir göstergesi olan eritrosit ve plazma malondialdehid (MDA) düzeyi ve antioksidan savunma sisteminin parametreleri olan eritrosit glutatyon peroksidaz (GPx), katalaz, süperoksit dismutaz (SOD) enzimlerinin aktiviteleri ölçüldü. Kontrol grubuna göre eritrosit ve plazma malondialdehid seviyesi hasta grubunda daha yüksek (p<0.0001), GPx ve SOD enzim aktivitesi hasta grubunda daha düşük (sırasıyla, p<0.0001 ve p<0.0001), katalaz enzim aktivitesi ise kontrol grubuna daha düşük (p<0.0001) bulundu. Hasta grubunda hem eritrosit hem de plazma MDA düzeyi diyaliz sonrası daha düşük (sırasıyla; p<0.0001, p<0.0001), GPx ve katalaz enzim aktivitesi diyaliz sonrası daha yüksek (p<0.05) bulundu. SOD enzim aktivitesinin diyaliz öncesi ve sonrası değerleri arasında fark bulunamadı (p>0.05). Bu çalışma sonucunda, hemodiyaliz hastalarında LP'nun sağlıklı kişilere göre arttığı ve hemodiyalizin tedavisinin oksidatif stresi azalttığ, kanaatine varıldı.
FULL TEXT (PDF): 
PDF icon pdf_tndt_294.pdf
  • 2
90-94
  • Turkish

REFERENCES

References: 

1. Loughrey CM, Young IS, Lightbody JH and et al. Q .1 Med 1994;87:679-683.
2.
Dasgupt
a A, Hussaain S, Ahmad S. Increased lipid
peroxidation in patients on maintenance hemodialysis.
Nephron 1992; 60: 56-59.
3. Cavanagh EMV, Ferder L, Carrasquedo F and et al. Higher levels of antioxidant defences in enalapril-treated versus non-enalapril-treated hemodialysis patients. Am J
Kidney Dis 1999; 34: 445-455.
4. Banni S, Lucchi L, Baraldi A and et al. No direct evidence of increased lipid peroxidation in hemodialysis
patients. Nephron 1996; 72: 177-183.
5. Çavdar C, Camsari T, Semin 1, and et al. Lipid peroxidation ant antioxidant activity in chronic
93
haemodialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol 1997; 31: 371-375.
6. Giardini O, Taccone-Gallucci T, Lubrano R and et al. Evidence of red blood cell membrane lipid peroxidation in haemodialysis patients. Nephron 1984; 36: 235-237.
7. Yalçın AS,Yurtkuran M, Dilek K and et al. The effect of vitamin E therapy on plasma and erythrocyte lipid peroxidation in chronic hemodialysis patients. Clinica ChimicaActa 1989; 185: 109-112.
8. Anderton JG, Thomas TH, Wilkinson R. Increased susceptibility to membrane lipid peroxidation in renal
failure. Nephron 1996; 74: 373-377.
9. Boaz M, Matas Z, Biro A and et al. Serum malondialdehyde and prevalent cardiovascular disease in
hemodiaysis. Kidney Int 1999; 56: 1078-1083.
10. Boaz M, Matas, Z, Biro A and et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999; 34: 438¬444.
11. Fairbanks VF, Klee GG. Measurement of hemoglobin concentration in whole blood. In: Tietz (ed) Textbook of Clinical Chemistry. WB Saunders, Philadelphia 1986, pp 1532-1534.
12. Paglia DE, Valentina WN. Studies on the quantitative and qualitastive characterization of enthrocyte glutatione
peroxidase. J Lab Clin Med 1967; 70: 158-169.
13. Aebi H. Catalase. in: Bergmeyer HU (ed). Methods of Enzymatic Analysis. Academic Press, New York 1974,
pp 673-684.
14. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem 1988; 34: 497¬500.
15. Cynamon HA, Isenberg .IN, Nguyen CH. Erythrocyte malondialdehyde release in vitro: afunctional measure of vitamin E status. Clinica Chimica Acta 1985; 151; 169¬176.
16. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal
Biochem 1979;95:351-358.
17. Taccone-Gallucci M, Giardini O, Lubrano R and et al. Red blood cell lipid peroxidation in predialysis chronic
renal failure. Clin Nephrol 1987; 27: 238-241.
18. Erden M. Serbest radikaller.T Klin Tıp Bilimleri 1992; 12: 201-207.

Thank you for copying data from http://www.arastirmax.com